Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 37, 2013, Pages 14960-14965

  Gu, Xiaoxiao ^a   Yu, Jane J ^b   Ilter, Didem ^a   Blenis, Nickolas ^a   Henske, Elizabeth Petri ^b   Blenis, John ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

EMT; ERK signaling; Estrogen signaling; mTORC1 signaling

Indexed keywords

ESTROGEN; INITIATION FACTOR 4B; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; S6 KINASE; S6 KINASE 1; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LYMPHANGIOLEIOMYOMATOSIS; PATHOGENESIS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EMT; ERK SIGNALING; ESTROGEN SIGNALING; MTORC1 SIGNALING;

ARABIDOPSIS PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; ESTRADIOL; EUKARYOTIC INITIATION FACTORS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MAP KINASE SIGNALING SYSTEM; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; PREGNANCY; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84883784055     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1309110110     Document Type: Article

References (30)

1. Bittmann I, Rolf B, Amann G, Löhrs U (2003) Recurrence of lymphangioleiomyomatosis after single lung transplantation: New insights into pathogenesis. Hum Pathol 34(1):95-98. (Pubitemid 36160028)
2. Karbowniczek M, et al. (2003) Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167(7):976-982. (Pubitemid 36408163)
3. Sato T, et al. (2002) Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47(1):20-28. (Pubitemid 34131970)
4. Yu J, Astrinidis A, Henske EP (2001) Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 164(8 Pt 1):1537-1540. (Pubitemid 33124040)
5. Yu J, Henske EP (2010) mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: The "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 8(1):43-49.
6. Henske EP, McCormack FX (2012) Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Clin Invest 122(11):3807-3816.
7. Harari S, Torre O, Moss J (2011) Lymphangioleiomyomatosis: What do we know and what are we looking for? European Respiratory Review: An Official Journal of the European Respiratory Society 20(119):34-44.
8. Matsui K, et al. (2000) Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124(11):1642-1648.
9. Yu J, Astrinidis A, Howard S, Henske EP (2004) Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and non-genomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 286(4):L694-L700. (Pubitemid 38365052)
10. Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97(11):6085-6090. (Pubitemid 30367527)
11. Strizheva GD, et al. (2001) The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 163(1):253-258. (Pubitemid 32095277)
12. McCormack FX, et al.; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595-1606.
13. Taillé C, Borie R, Crestani B (2011) Current management of lymphangioleiomyomatosis. Curr Opin Pulm Med 17(5):374-378.
14. Safe S, Kim K (2008) Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41(5):263-275.
15. Cohen MM, Freyer AM, Johnson SR (2009) Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 103(5):766-772.
16. De Pauw RA, et al. (2003) Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis. Am J Kidney Dis 41(4):877-883. (Pubitemid 36396756)
17. Karbowniczek M, Robertson GP, Henske EP (2006) Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 281(35):25447-25456. (Pubitemid 44401933)
18. Yu JJ, et al. (2009) Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 106(8):2635-2640.
19. Murphy LO, MacKeigan JP, Blenis J (2004) A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol 24(1):144-153. (Pubitemid 38010042)
20. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4(8):556-564.
21. Murphy LO, Blenis J (2006) MAPK signal specificity: The right place at the right time. Trends Biochem Sci 31(5):268-275. (Pubitemid 43674354)
22. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J (2010) ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 38(1):114-127.
23. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5):307-318.
24. Holz MK, Ballif BA, Gygi SP, Blenis J (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123(4):569-580. (Pubitemid 41608461)
25. Shin S, Blenis J (2010) ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition. Cell Cycle 9(13):2483-2484.
26. Vial E, Marshall CJ (2003) Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J Cell Sci 116(Pt 24):4957-4963. (Pubitemid 38016702)
27. Casanova A, Ancochea J (2011) [Lymphangioleiomyomatosis: New therapeutic approaches]. Arch Bronconeumol 47(12):579- 580.
28. Mackeigan JP, Murphy LO, Dimitri CA, Blenis J (2005) Graded mitogen-activated protein kinase activity precedes switch-like c-Fos induction in mammalian cells. Mol Cell Biol 25(11):4676-4682. (Pubitemid 40705770)
29. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36(6):320-328.
30. Arbiser JL, et al. (2001) The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: Use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol 159(2):483-491. (Pubitemid 32751079)